Skip to content

Cerenis Therapeutics announces the initiation of the Phase 1 clinical study with CER-209 in NAFLD and NASH

TOULOUSE, France and ANN ARBOR, Mich. (Avril 18, 2017 at 8.00 am CET) – Cerenis Therapeutics (FR0012616852 – CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today announces that de Phase 1 clinical trial with CER-209, a P2Y13 receptor agonist, has been initiated.

Please find attached the full PDF file related to this information. 

About CER-209

CER-209 is the first drug candidate in the category of oral P2Y13 receptor agonists. The P2Y13 receptor is a member of the P2Y receptor family, a well-known receptor family including the P2Y12 receptor that is the target of successful drugs such as the anti-thrombotic agent Clopidogrel (Plavix®). CER-209 is a specific agonist of the P2Y13 receptor and does not interact with the P2Y12 receptor. In preclinical studies CER-209 promotes HDL recognition by the liver and increases Reverse Lipid Transport (RLT), thereby impacting atherosclerosis regression. Because of the favorable metabolic effects observed in the liver, CER 209 may also offer a new mechanism for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

 

About Cerenis Therapeutics: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL and other therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.  Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). Cerenis is well positioned to become one of the leaders in this innovative lipid metabolism therapeutic market, with a broad portfolio of programs in development.

●●●

CONTACTS

Cerenis  
CEO
Jean-Louis Dasseux
Tel: +33 (0)5 62 24 09 49
info@cerenis.com
NewCap 
Investor relations
Emmanuel Huynh / Louis-Victor Delouvrier
Media relations
Nicolas Merigeau

Tel: +33 (0)1 44 71 98 53
cerenis@newcap.eu


Source: Cerenis